Skip to main content

AS/Spondyloarthritis

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Sep 23, 2021

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID

Read Article
Breakthrough infections from UK QResarch database: Among 6.95 million vaccinated, 74.1% recv two vaccine doses, there were 2031 covid-19 deaths & 1929 hosp admissions; ~4.0% deaths & admissions were >14 days after 2nd dose https://t.co/bbDsb1zLhX

Dr. John Cush @RheumNow( View Tweet )

Sep 20, 2021

ACR Comments on JAK Inhibitors and FDA Announcement

ACR
Sep 13, 2021

Following is a statement from ACR President David Karp, MD, PhD, on JAK inhibitors and FDA drug safety communication.

Read Article

Lymphoma in RA: Disease Activity Matters

MedPage Today
Sep 08, 2021

Among patients with rheumatoid arthritis (RA), the strongest risk factors for the development of lymphoma were disease activity and severity, French researchers found.

In a multivariate analysis, having a high Disease Activity Score in 28 joints (DAS28) at baseline conferred twice the risk for

Read Article

COVID Breakthrough Infections in Rheumatic Patients

Sep 08, 2021

Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with systemic autoimmune rheumatic diseases (SARDs) are not uncommon, and may be severe or fatal.



Researchers

Read Article
FDA JAK inhibitor warnings and what it means (also: what do you think?); other news released this week; and, two questions submitted from listeners. Dr. Cush discusses this and more in this week's podcast. https://t.co/4jTBhYDzRn https://t.co/lMpl2IOeXe
Dr. John Cush @RheumNow( View Tweet )
Sep 03, 2021

Expert Panel: Initial Views on FDA Warnings for JAK Inhibitors

Sep 02, 2021

Dr. Jack Cush is joined by Drs. Roy Fleischmann (Dallas), Allan Gibofsky (NYC), and Artie Kavanaugh (San Diego) to discuss the 9/2/21 FDA Drug Safety Communication regarding the cardiovascular and cancer risks arising from the Pfizer 1133 (ORAL Surveillance) tofacitinib study, but also applied

Read Article

FDA: New Cardiac and Cancer Warnings for All JAK Inhibitors

Sep 01, 2021

Today, Sept.1st, the FDA announced its decision regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co.

These safety concerns arise from

Read Article
Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing PsA, psoriasis, RA, and AS showed both shared and differentiating risk factors, but statin use was protective in all 4 conditions. https://t.co/qXlpKVwwWg https://t.co/08jF5jPEH0
Dr. John Cush @RheumNow( View Tweet )
Sep 01, 2021

Predictors of Inflammatory Arthritis

Aug 31, 2021

Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing psoriatic arthritis (PsA), psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) showed both shared and differentiating risk factors, but statin use was

Read Article
Can an anti-inflammatory diet impact axial spondyloarthritis (axSpA)? A 6-month dietary intervention shows that adherence to a Mediterranean diet lowers disease activity in axSpA; but dietary adherence is often incomplete. https://t.co/AqtYO60XbH https://t.co/uYil2YvOR1
Dr. John Cush @RheumNow( View Tweet )
Aug 30, 2021

RheumNow Podcast – COVID Marching Amidst the Madness (8.27.2021)

Aug 26, 2021

We have a lot of news, information and approvals to review and discuss, though I need to begin with what's weighing heavily on my mind. After, we'll dive into what we learned this week.

Read Article
2021–22 influenza season coincides with continued COVID infx & Sxs may be confused betw both. ACIP Influenza vaccination guidelines: 1. Annual flu vaccine rec to all >6mos; 2. COVID Vax can be given w/ Flu Vax; 3. give before Nov 2021 https://t.co/oIkl50GI0W

Dr. John Cush @RheumNow( View Tweet )

Aug 26, 2021

Mediterranean Diet Benefits Spondyloarthritis

Aug 26, 2021

Can an antiinflammatory diet impact axial spondyloarthritis (axSpA)? A 6-month dietary intervention shows that adherence to a Mediterranean diet lowers disease activity in axSpA; but dietary adherence is often incomplete.



This prospective, 6 month trial assessed whether nutritional

Read Article

ACR Guidance on Timing of 3rd Dose Booster with Immunomodulatory Drugs

ACR Press Release
Aug 25, 2021

The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and Musculoskeletal Diseases following recent recommendations from the CDC that certain immunocompromised patients receive a third dose of an available mRNA

Read Article
Among pregnant women, receipt of the BNT162b2 vaccine was associated with a 78% lower risk of incident SARS-CoV-2 infection. Cohort study tincluded 15 060 pregnant women in Israel. No adverse pregnancy outcome difference in Vax Pts https://t.co/jXUjaKIfUV

Dr. John Cush @RheumNow( View Tweet )

Aug 25, 2021
Rheums--have a question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wzNmOzH4VE https://t.co/QJn6Uo3lbM
Dr. John Cush @RheumNow( View Tweet )
Aug 24, 2021
The CDC has reported that mRNA vaccine effectiveness against COVID-19–associated hospitalizations was sustained over 24 weeks; but there is evidence of waning protection amongst the immunosuppressed. https://t.co/UpQjFgKTpE https://t.co/3dQ2jacwJD
Dr. John Cush @RheumNow( View Tweet )
Aug 23, 2021

Oligoarticular vs. Polyarticular Psoriatic Arthritis

Aug 19, 2021

A psoriatic arthritis (PsA) cohort analysis reveals many similarities and few distinctions between those who present with oligoarticular and polyarticular PsA.



A total of 402 PsA patients from the University of Toronto PsA clinic (1978 - 2018) were included. Oligoarthritis was defined

Read Article
Chronologic Progression of Ankylosing Spondylitis https://t.co/ihVVystOMn https://t.co/SXhkkBgzTJ
Dr. John Cush @RheumNow( View Tweet )
Aug 12, 2021

Biologics Reduce Surgical Needs in RA

Aug 10, 2021

In Canada, biologic DMARDs (bDMARDs) were introduced after 2001, and since that time there have been significant reductions in hip and knee arthroplasty (THA/TKA) among patients with rheumatoid arthritis (RA), but not in patients with osteoarthritis (OA).



A cohort of RA and OA

Read Article
The TORTUGA trial tested filgotinib, a JAK1 inhibitor, in active ankylosing spondylitis (AS) patients and was shown to be both effective and capable of retarding sacroiliac (SI) joint erosions as early as 12 weeks. https://t.co/awfZdiTUBt https://t.co/ST2JIkavhy
Dr. John Cush @RheumNow( View Tweet )
Aug 10, 2021

Early MRI Sacroiliac Improvement with JAK Inhibition

Aug 09, 2021

The TORTUGA trial tested filgotinib, a JAK1 inhibitor, in active ankylosing spondylitis (AS) patients and was shown to be both effective and capable of retarding sacroiliac (SI) joint erosions as early as 12 weeks.



Adults AS patients were enrolled after an inadequate response to ≥ 2

Read Article

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

Aug 06, 2021

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article

Rheumatic Flares Uncommon After COVID Vax

MedPage Today
Aug 04, 2021

Post-vaccination disease flares were uncommon among patients with rheumatic and musculoskeletal diseases who were inoculated against COVID-19, researchers found.



Among 1,377 patients who were given two doses of a SARS-CoV-2 mRNA vaccine, 11% reported a flare of their underlying

Read Article
×